Adjuvant immunotherapy improves survival in completely resected stage IB–III NSCLC: a systematic review and meta-analysis

Adjuvant immunotherapy improves survival in completely resected stage IB–III NSCLC: a systematic review and meta-analysis

BackgroundThe clinical benefits of postoperative chemotherapy for non-small cell lung cancer (NSCLC) have plateaued, thus highlighting the need for novel strategies. This meta-analysis evaluated the efficacy and safety of adjuvant immunotherapy in patients with completely resected NSCLC and wild-typ...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hong Huang, Pengchen Bao, Hongyu Jin, Wenyang Li, Hui Shen, Zhen Qin, Ying Pan, Xinming Su, Delei Kong
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-04-01
Series:	Frontiers in Oncology
Subjects:	adjuvant immunotherapy immune checkpoint inhibitors ICIs non-small cell lung cancer NSCLC
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1493221/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Sex-Related Differences in Immunotherapy Outcomes of Patients with Advanced Non-Small Cell Lung Cancer
by: Sara Frida Cohen, et al.
Published: (2024-11-01)

Impact of thyroid immune-related adverse events on clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibitor therapy: A single center study
by: Šejla Cerić, et al.
Published: (2025-03-01)

The role of COPD in survival of NSCLC patients receiving immune checkpoint inhibitors: A meta-analysis
by: Yan Zhu, et al.
Published: (2025-05-01)

Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non‐small cell lung cancer
by: Pei Zhang, et al.
Published: (2021-01-01)

Is adjuvant immunotherapy necessary after neoadjuvant chemoimmunotherapy in patients with resectable stage III NSCLC? A two-center real-world study
by: Song Guan, et al.
Published: (2025-07-01)

Thioredoxin: a key factor in cold tumor formation and a promising biomarker for immunotherapy resistance in NSCLC
by: Jiayi Hu, et al.
Published: (2025-05-01)

Perioperative Chemo/Immunotherapies in Lung Cancer: A Critical Review on the Value of Perioperative Sequences
by: Thoma’ Dario Clementi, et al.
Published: (2025-07-01)

Prognostic Impact of Adjuvant Immunotherapy in Patients With Resectable NSCLC After Neoadjuvant Chemoimmunotherapy: A Brief Report
by: Yichen Dong, MD, et al.
Published: (2025-01-01)

CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB–IIIA NSCLC
by: Jay M. Lee, MD, et al.
Published: (2025-08-01)

A prospective multi-cohort study identifies and validates a 5-gene peripheral blood signature predictive of immunotherapy response in non-small cell lung cancer
by: Shaoqiu Chen, et al.
Published: (2024-11-01)

Neoadjuvant immune checkpoint inhibitor reduced recurrence in operable NSCLC patients with pathological complete response: a retrospective analysis
by: Yanxiong Mao, et al.
Published: (2024-11-01)

Antibiotic Use and Survival in Patients With Late-Stage NSCLC Treated With Chemoimmunotherapy
by: Emanuela Taioli, MD, PhD, et al.
Published: (2024-12-01)

Development and validation of a nomogram for predicting immune-related thyroid dysfunction during immunotherapy in non-small cell lung cancer: a prospective cohort study in China
by: Qianjie Xu, et al.
Published: (2025-07-01)

HCC and Immunotherapy: The Potential Predictive Role of Gut Microbiota and Future Therapeutic Strategies
by: Carmelo Laface, et al.
Published: (2025-02-01)

Advancing Adjuvant Immunotherapy in Hepatocellular Carcinoma: A Comprehensive Review
by: Akabane M, et al.
Published: (2025-06-01)

Perioperative Management of Non-Small Cell Lung Cancer in the Era of Immunotherapy
by: Ulas Kumbasar, et al.
Published: (2025-06-01)

Adjuvant therapy in resected non-small cell lung cancer: current status and perspectives
by: Robert Pirker
Published: (2025-03-01)

Continuous immunotherapy beyond disease progression in patients with advanced non-small cell and small cell lung cancer
by: Jing Cheng, et al.
Published: (2025-02-01)

The immunotherapy breakthroughs in cervical cancer: Focus on potential biomarkers and further therapy advances
by: Maja Pezer Naletilić, et al.
Published: (2025-05-01)

The Impact of Immune Checkpoint Inhibitors on Fertility Preservation and Pregnancy Outcomes
by: Agata Prokopiuk, et al.
Published: (2025-05-01)

CK2B Induces CD8+ T‐Cell Exhaustion through HDAC8‐Mediated Epigenetic Reprogramming to Limit the Efficacy of Anti‐PD‐1 Therapy in Non‐Small‐Cell Lung Cancer
by: Shaochuan Liu, et al.
Published: (2025-04-01)

Association between opioid use and survival in advanced non small cell lung cancer patients treated with immune checkpoint inhibitors
by: Luigi Liguori, et al.
Published: (2025-08-01)

Opportunities, obstacles and challenges of nano-immunotherapy in melanoma
by: Zexing Shan, et al.
Published: (2025-08-01)

Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance
by: Jin Tian, et al.
Published: (2024-12-01)

Targeting immune checkpoints in hepatocellular carcinoma therapy: toward combination strategies with curative potential
by: Jing Tong, et al.
Published: (2025-05-01)

Immunization with Complete Freund’s Adjuvant Reveals Trained Immunity-like Features in A/J Mice
by: Kiruthiga Mone, et al.
Published: (2025-07-01)

Oligometastatic NSCLC: Current Perspectives and Future Challenges
by: Sara Torresan, et al.
Published: (2025-01-01)

Durable immunotherapeutic response in molecularly complex pulmonary adenosquamous carcinoma: case report and literature review
by: Jun Zhu, et al.
Published: (2025-06-01)

KRAS Mutations as Predictive Biomarkers for First-Line Immune Checkpoint Inhibitor Monotherapy in Advanced NSCLC: A Systematic Review and Meta-Analysis
by: Filip Marković, et al.
Published: (2025-06-01)

Preliminary Real-World Outcomes of Adjuvant Immunotherapy in Resected Esophageal Cancer: A Retrospective Study from Taiwan
by: Chia Liu, et al.
Published: (2025-07-01)

Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy
by: Anna De Lucia, et al.
Published: (2025-02-01)

Real‐world experience of adjuvant immunotherapy for stages III–IV melanoma: A monocentric observational study
by: Manon Blaise, et al.
Published: (2025-06-01)

Fluorescence Lifetime Imaging of NAD(P)H in Patients’ Lymphocytes: Evaluation of Efficacy of Immunotherapy
by: Diana V. Yuzhakova, et al.
Published: (2025-01-01)

The Role of Eosinophils, Eosinophil-Related Cytokines and AI in Predicting Immunotherapy Efficacy in NSCLC
by: Fausto Omero, et al.
Published: (2025-03-01)

Does Pre-Existing Chronic Obstructive Pulmonary Disease Increase the Risk of Checkpoint Inhibitor Pneumonitis in Advanced/Metastatic Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors?
by: David Spillane, et al.
Published: (2025-04-01)

Impact of Immune Checkpoint Inhibitors and Local Radical Treatment on Survival Outcomes in Synchronous Oligometastatic NSCLC
by: Mandy Jongbloed, MD, et al.
Published: (2025-03-01)

Adjuvant brachytherapy for Stage IB Grade 2 endometrial carcinoma: Multivariate analysis of a single institution experience
by: Margarita Tokar, et al.
Published: (2016-01-01)

Gut Microbiota Reshapes the Tumor Microenvironment and Affects the Efficacy of Colorectal Cancer Immunotherapy
by: Fayuan Wang, et al.
Published: (2025-06-01)

Limited benefit of adjuvant chemotherapy for Asian patients with stage IB lung adenocarcinoma: implications for clinical practice
by: Shaowei Xin, et al.
Published: (2025-07-01)

Survival outcomes and prognostic impact of adjuvant chemotherapy in stage IB lung adenocarcinoma with cribriform component
by: Rongyang Li, et al.
Published: (2025-07-01)